Jimandin

Sitagliptin, the active ingredient in Jimandin, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It improves glycemic control by enhancing insulin secretion and reducing glucagon release, and is indicated for the management of type 2 diabetes mellitus in adults when combined with diet and exercise.

GNH USA supplies Jimandin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for export to EU and other markets.

Jimandin (sitagliptin) is used to improve glycemic control in patients with type 2 diabetes mellitus. - Type 2 diabetes mellitus: improves blood glucose levels when used with diet and exercise. - Combination therapy with metformin: provides additional glucose‑lowering effect for patients inadequately controlled on metformin alone. - Monotherapy in patients intolerant to other oral agents: offers an alternative mechanism to achieve glycemic control.

The most frequently reported and clinically significant adverse reactions to sitagliptin are listed below.

Common Side Effects: - Nausea - Headache - Nasopharyngitis - Upper respiratory tract infection

Serious or Rare Side Effects: - Pancreatitis - Severe allergic reactions (e.g., anaphylaxis) - Bullous skin disorders such as pemphigoid

When prescribing Jimandin, clinicians should consider the following precautions to ensure safe use. - Renal function assessment: evaluate kidney function and adjust dose in severe impairment. - Monitor for pancreatitis: advise patients to report persistent abdominal pain or vomiting. - Assess hepatic function: use with caution in patients with liver disease. - Avoid in patients with known hypersensitivity to sitagliptin or any excipients. - Pregnancy and lactation: discuss potential risks with the prescriber before use. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Sitagliptin may interact with other medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase sitagliptin plasma concentrations. - Insulin secretagogues (e.g., sulfonylureas): heightened risk of hypoglycemia. - Rifampin: may reduce sitagliptin effectiveness.

Moderate Interactions (Monitor Closely): - Diuretics: may affect glucose control, monitor blood sugar. - ACE inhibitors: observe renal function when combined. - Beta‑blockers: can mask symptoms of hypoglycemia.